Reference : Cibler la voie métabolique du cortisol comme action thérapeutique dans le diabète de ...
Scientific journals : Article
Human health sciences : Endocrinology, metabolism & nutrition
Cibler la voie métabolique du cortisol comme action thérapeutique dans le diabète de type 2
[en] Targeting the metabolic pathway of cortisol as a potential therapy of type 2 diabetes
Scheen, André mailto [Université de Liège - ULiège > Département des sciences cliniques > Département des sciences cliniques >]
Médecine des Maladies Métaboliques
Elsevier Masson SAS
[en] Cortisol ; Article ; Cushing syndrome
[en] The 11ß-hydroxysteroid dehydrogenase type 1 (11βHSD1) enzyme promotes the local conversion from inactive cortisone to active cortisol. It may play a role in the pathophysiology of abdominal obesity and the metabolic syndrome, both showing some similarities with the Cushing syndrome. Synthetic selective inhibitors of 11βHSD1 have been investigated in pilot studies in overweight/obese patients with type 2 diabetes or hypertension. Although some positive effects were observed, they were considered as too modest compared to what could be obtained with other available drugs. More recently, a reduction in liver steatosis was reported in overweight/obese non-diabetic patients. Whereas some early 11βHSD1 inhibitors have been abandoned, others are still in development, which demonstrates a persisting interest for this innovative therapeutic approach. © 2016 Elsevier Masson SAS

File(s) associated to this reference

Fulltext file(s):

Open access
2016 MMM cortisol A Scheen.pdfPublisher postprint1.25 MBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.